Major boost for Leicester spin-out company Haemostatix

UK-based Ergomed plc, a company specialising in services to the pharmaceutical industry and new drug development, has acquired Haemostatix Ltd, originally a University of Leicester spin-out company.

The move signals further confidence in the technologies developed by Haemostatix including an innovative clotting agent to help control bleeding during surgery.

Ergomed is acquiring 100 per cent of the issued share capital of Haemostatix for an initial consideration of £8.0 million, with contingent consideration of a further £20.0 million dependent on future development and sales.

Nottingham-based Haemostatix, which started life at the University of Leicester is developing a new class of topical clotting agents. The technology is based on a novel class of molecule that binds directly to fibrinogen to promote haemostasis and is targeted at the global surgical bleeding market, worth more than $2 billion.

The two lead products developed by the Haemostatix team are PeproStat (Phase IIb ready), a blood-free, ready-to-use topical liquid haemostat which is applied to wounds to control bleeding during surgery, and ReadyFlow (pre-clinical), a blood-free, ready to use, transparent and flowable haemostatic gel packaged in a pre-filled syringe. 

Haemostatix was originally a spin-out from the University of Leicester founded by industry veteran Sarah Middleton and Professor Alison Goodall. The Company has been funded by Albion Ventures, Catapult Ventures, NESTA, Lachesis, Esperante and the Wellcome Trust.